The labs that utilize MOMS haven't just close their collection gaps. They changed the trajectory of their revenue, their client relationships, and their competitive position in markets they were previously losing orders in.
That's the part of the collection infrastructure conversation that June and July's content didn't fully reach. We spent the past two months of content topics on the problem, the infrastructure decision, and the compliance burden. August is about what's on the other side.
Better collection access isn't a cost center investment that produces operational stability. It's a revenue recovery strategy, a physician retention mechanism, and a competitive positioning move — and the labs that have made it consistently describe a meaningfully different business as a result.
Most specialty labs manage their financial performance against revenue realized — the tests that were ordered, collected, processed, and billed successfully. That's the number that shows up in monthly reporting. It's also incomplete.
The number that reveals what better collection access actually produces is the gap between revenue per test ordered and revenue per test completed. That gap is the collection gap, measured in dollars.
At a70% completion rate on 2,000 monthly orders at $150 average value, the gap between ordered and realized revenue is $90,000 per month. $1.08 million annually. Not lost to billing errors or payer rejections. Lost before a specimen ever reached the lab.
The labs that have run this number by geography — not just in aggregate — consistently find that the gap is larger than their overall completion rate suggests, and that it's concentrated in specific markets where collection infrastructure is thin or absent.
Closing 10% of that gap doesn't require acquiring new clients, launching new tests, or renegotiating payer contracts. It requires completing more of the orders that are already there — in the markets where the infrastructure currently fails them.
For a lab processing 2,000 monthly orders, a 10-point improvement in completion rate recovers $108,000 in annual revenue from orders the lab already has. At higher volumes or higher per-draw values, the recovery scales proportionally.
That's the first-order financial outcome of better collection access: the gap between what was ordered and what was realized narrows, and the revenue that narrows it came from work the lab's commercial team already did.
The second-order outcome is. harder to measure precisely and more consequential than the direct revenue recovery.
Ordering physician relationships don't typically end in a single conversation. They erode. A physician whose patients consistently complete draws and receive results builds a quiet loyalty to the lab that made that possible. A physician whose patients encounter access friction — incomplete draws, re-draw requests, results that arrive late or not at all — starts routing similar cases elsewhere. The volume decline appears in the data several months after the decision was made.
The labs that have the most stable ordering physician relationships share a specific characteristic: their completion rates are reliable across geographies, not just in their home market. The physician in a tertiary city whose patients include a meaningful share of rural or semi-rural residents knows their results will come back — not because they've specifically audited the lab's rural coverage, but because they've never had to.
The labs retaining their best ordering physician relationships aren't the ones with the best clinical marketing. They're the ones whose patients reliably complete draws — in every market where those patients live.
MOMS provides the collection coverage that makes reliable completion possible outside a lab's home market — in the rural counties, smaller MSAs, and underserved geographies where physicians' patient panels often include a larger share of access-challenged patients than urban-centric collection infrastructure can reach.
The third outcome is specific to specialty labs in the commercialization phase: new test launches perform materially better when collection infrastructure is in place before the orders start.
A test launched into a national market with reliable collection coverage in the top 100 MSAs and meaningful rural depth performs closer to its commercial model because the completion rate is baked into the infrastructure, not discovered after launch. Revenue ramps faster. Physician adoption data is cleaner. Payer negotiations happen against a completion rate that reflects actual clinical performance, not an access-impaired proxy for it.
A test launched into the same market with collection infrastructure that covers 60% of the expected ordering geography produces a launch that looks underperforming on every metric — even if the science, the clinical positioning, and the physician relationships are exactly right. The data that comes back from the first 90 days of a poorly-covered launch is wrong in ways that are hard to correct for and that can drive bad commercial decisions.
The labs that have consistently strong test launch performance have learned to treat collection coverage as a pre-launch requirement, not a post-launch discovery. They map their expected ordering geography against their collection network depth before the first orders go out — and they close the gaps while there's still time to close them without disrupting an active commercial program.
The aggregate of these three outcomes is a competitive position that compounds in ways that are difficult to replicate quickly.
A lab with higher completion rates recovers more revenue from the same order volume. That revenue funds deeper clinical investment, broader geographic expansion, and the commercial resources to build new physician relationships in markets competitors haven't entered.
A lab with stable physician retention doesn't spend the same portion of its commercial bandwidth on replacing physician relationships it's quietly losing. That attention goes toward expanding the network rather than maintaining it.
A lab with a track record of strong test launch performance attracts the kind of clinical development partnerships, health system relationships, and payer contracts that require demonstrated commercial execution — not just clinical viability.
The labs with the strongest collection access infrastructure aren't just operationally better than their peers. They're commercially better. And the gap between them and the labs still treating collection as a logistics afterthought grows with each quarter the infrastructure difference persists.
MOMS is the Connection for the Collection™ — and the outcomes described above are what that connection actually produces for specialty labs that use it.
National geographic reach in markets most collection networks don't reliably cover. Credentialed, trained MAPs who complete specialty draws to the standard the lab requires. Sticklogistics® training that ensures every MAP knows the lab's specific kit protocols, chain of custody requirements, and deviation reporting procedures before their first draw. Compliance infrastructure that runs in the background without requiring a dedicated lab operations function to maintain it.
The outcome isn't just better collection metrics. It's a lab that operates with more revenue, stronger physician relationships, and a more credible commercial platform than it had before.
That's what better collection access actually produces.